Financial

News

Novo Nordisk's new chief executive Mike Doustdar

Novo Nordisk cuts guidance again on weaker GLP-1 growth

Novo Nordisk's first set of financial results under new CEO Mike Doustdar continues the theme of lower growth expectations for the company this year.

News

MSD still seeking deals 'with urgency' after Verona takeover

MSD has only just completed its $10 billion takeover of Verona Pharma, but is still on the hunt for more bolt-on acquisitions.

News

Lilly climbs on stellar GLP-1 drug sales gain

Eli Lilly is celebrating a massive 54% increase in its third-quarter revenues to $17.6 billion, driven by its medicines for diabetes and obesity.

News

Specialty meds lift GSK's outlook in Walmsley's swan song

Emma Walmsley's last set of financial results as GSK's chief executive has gone swimmingly, allowing the company to raise its 2025 forecasts.

News

Falling flu vaccine sales in US stall CSL's Seqirus spinout

CSL says flu vaccination rates in the US are expected to fall 12% to 14% this year, and have scuppered its plan to spin out its vaccines unit Seqirus.

News

Novartis' new drugs outweigh Entresto decline in Q3

Now feeling the impact of generic competition on its top product Entresto in the US, Novartis is still looking for pipeline-building deals, says CEO.

Novo Nordisk cuts guidance again on weaker GLP-1 growth

MSD still seeking deals 'with urgency' after Verona takeover

Lilly climbs on stellar GLP-1 drug sales gain

Specialty meds lift GSK's outlook in Walmsley's swan song

Falling flu vaccine sales in US stall CSL's Seqirus spinout

Novartis' new drugs outweigh Entresto decline in Q3

Novo sues Lilly over 'misleading' GLP-1 ad campaigning

Discover a new era of healthcare panel engagement: Grounded ...

Financial

Editor's Picks